FI930846A0 - HOMOCONJUGERADE IMMUNOGLOBULINER - Google Patents
HOMOCONJUGERADE IMMUNOGLOBULINERInfo
- Publication number
- FI930846A0 FI930846A0 FI930846A FI930846A FI930846A0 FI 930846 A0 FI930846 A0 FI 930846A0 FI 930846 A FI930846 A FI 930846A FI 930846 A FI930846 A FI 930846A FI 930846 A0 FI930846 A0 FI 930846A0
- Authority
- FI
- Finland
- Prior art keywords
- immunoglobuliner
- homoconjugerade
- homoconjugerade immunoglobuliner
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57572590A | 1990-08-31 | 1990-08-31 | |
| US74866291A | 1991-08-26 | 1991-08-26 | |
| PCT/US1991/006195 WO1992004053A1 (en) | 1990-08-31 | 1991-08-29 | Homoconjugated immunoglobulins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI930846A0 true FI930846A0 (en) | 1993-02-25 |
| FI930846A7 FI930846A7 (en) | 1993-04-05 |
| FI930846L FI930846L (en) | 1993-04-05 |
Family
ID=27076774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI930846A FI930846L (en) | 1990-08-31 | 1991-08-29 | HOMOCONJUGERADE IMMUNOGLOBULINER |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0547137A4 (en) |
| JP (1) | JPH06500780A (en) |
| KR (1) | KR930702029A (en) |
| AU (1) | AU8506991A (en) |
| CA (1) | CA2090317A1 (en) |
| FI (1) | FI930846L (en) |
| IE (1) | IE913071A1 (en) |
| IL (1) | IL99363A0 (en) |
| NZ (1) | NZ239617A (en) |
| PT (1) | PT98840A (en) |
| WO (1) | WO1992004053A1 (en) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2281300A (en) * | 1993-08-26 | 1995-03-01 | Merck & Co Inc | Anti-HIV antibody oligomer |
| WO1999002567A2 (en) * | 1997-07-08 | 1999-01-21 | Board Of Regents, The University Of Texas System | Compositions and methods for producing homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US8188231B2 (en) | 2002-09-27 | 2012-05-29 | Xencor, Inc. | Optimized FC variants |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| US9051373B2 (en) | 2003-05-02 | 2015-06-09 | Xencor, Inc. | Optimized Fc variants |
| US9714282B2 (en) | 2003-09-26 | 2017-07-25 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
| US20150010550A1 (en) | 2004-07-15 | 2015-01-08 | Xencor, Inc. | OPTIMIZED Fc VARIANTS |
| DK1817340T3 (en) | 2004-11-12 | 2012-08-13 | Xencor Inc | FC VARIATIONS WITH CHANGED BINDING TO FCRN |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CA2624189A1 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| AU2006302254B2 (en) | 2005-10-06 | 2011-05-26 | Xencor, Inc. | Optimized anti-CD30 antibodies |
| ME01786B (en) | 2006-08-14 | 2014-09-20 | Xencor Inc | Optimized antibodies that target cd19 |
| AU2007299843B2 (en) | 2006-09-18 | 2012-03-08 | Xencor, Inc | Optimized antibodies that target HM1.24 |
| EP2235059B1 (en) | 2007-12-26 | 2015-02-18 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| US12492253B1 (en) | 2008-02-25 | 2025-12-09 | Xencor, Inc. | Anti-human C5 antibodies |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| PE20120591A1 (en) | 2009-04-02 | 2012-05-23 | Roche Glycart Ag | MULTI-SPECIFIC ANTIBODIES INCLUDING FULL-LENGTH ANTIBODIES AND SINGLE-CHAIN FAB FRAGMENTS |
| WO2010112194A1 (en) | 2009-04-02 | 2010-10-07 | F. Hoffmann-La Roche Ag | Antigen-binding polypeptides and multispecific antibodies comprising them |
| EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
| BRPI1012589A2 (en) | 2009-04-07 | 2016-03-22 | Roche Glycart Ag | bispecific antibodies anti-erbb-3 / anti-c-met |
| CA2757669A1 (en) | 2009-04-07 | 2010-10-14 | Roche Glycart Ag | Bispecific anti-erbb-1/anti-c-met antibodies |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| AU2010296018B2 (en) | 2009-09-16 | 2016-05-05 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| WO2011091078A2 (en) | 2010-01-19 | 2011-07-28 | Xencor, Inc. | Antibody fc variants with enhanced complement activity |
| AR080793A1 (en) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | BISPECIFIC ANTIBODIES |
| AR080794A1 (en) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | BIVING SPECIFIC ANTIBODIES ANTI-VEGF / ANTI-ANG-2 |
| JP5758004B2 (en) | 2010-08-24 | 2015-08-05 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Bispecific antibodies comprising Fv fragments stabilized by disulfides |
| SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| RU2644341C2 (en) | 2012-02-10 | 2018-02-08 | Дженентек, Инк. | Single-chain antibodies and other heteromultimers |
| CN104245738B (en) | 2012-04-05 | 2018-02-02 | 弗·哈夫曼-拉罗切有限公司 | For people TWEAK and people IL17 bispecific antibody and application thereof |
| JP6203838B2 (en) | 2012-06-27 | 2017-09-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Method for selecting and creating tailor-made highly selective and multispecific targeting entities comprising at least two different binding entities and uses thereof |
| EP2867254B1 (en) | 2012-06-27 | 2017-10-25 | F. Hoffmann-La Roche AG | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| RU2684595C2 (en) | 2012-07-04 | 2019-04-09 | Ф.Хоффманн-Ля Рош Аг | Kovalent-related conjuates of antigen-antibody |
| CA2872192A1 (en) | 2012-07-04 | 2014-01-09 | F. Hoffmann-La Roche Ag | Anti-biotin antibodies and methods of use |
| EP3138578B1 (en) | 2012-07-04 | 2022-01-12 | F. Hoffmann-La Roche AG | Anti-theophylline antibodies and methods of use |
| CN104341504B (en) | 2013-08-06 | 2017-10-24 | 百奥泰生物科技(广州)有限公司 | Bispecific antibody |
| CA2932958A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
| WO2015101586A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
| CA2930154A1 (en) | 2014-01-03 | 2015-07-09 | F. Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
| EP3089759B1 (en) | 2014-01-03 | 2018-12-05 | F. Hoffmann-La Roche AG | Covalently linked polypeptide toxin-antibody conjugates |
| AR100978A1 (en) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
| JP6721590B2 (en) | 2014-12-03 | 2020-07-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Multispecific antibody |
| EP3744732B1 (en) | 2015-06-24 | 2025-09-10 | F. Hoffmann-La Roche AG | Humanized anti-tau(ps422) antibodies and methods of use |
| KR20230136699A (en) | 2016-06-06 | 2023-09-26 | 노쓰웨스턴유니버시티 | Fusion protein construct |
| RU2020113059A (en) | 2017-11-07 | 2021-12-08 | Хьюбит Дженомикс,Инк. | METHOD FOR PRIMARY PREVENTION OF ALLERGIC DISEASES IN INFANT CHILDREN USING SPECIFIC IMMUNOSUPPRESSION OF IGE CLASS IMMUNOGLOBULINS |
| WO2025129010A1 (en) | 2023-12-14 | 2025-06-19 | Genentech, Inc. | Methods of structure determination using antibodies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422653D0 (en) * | 1984-09-07 | 1984-10-10 | Technology Licence Co Ltd | Monoclonal antibodies |
| CA2045150A1 (en) * | 1989-11-07 | 1991-05-08 | Walt W. Shuford | Oligomeric immunoglobulins |
-
1991
- 1991-08-29 JP JP3515144A patent/JPH06500780A/en active Pending
- 1991-08-29 KR KR1019930700605A patent/KR930702029A/en not_active Withdrawn
- 1991-08-29 AU AU85069/91A patent/AU8506991A/en not_active Abandoned
- 1991-08-29 CA CA002090317A patent/CA2090317A1/en not_active Abandoned
- 1991-08-29 EP EP19910916502 patent/EP0547137A4/en not_active Ceased
- 1991-08-29 FI FI930846A patent/FI930846L/en unknown
- 1991-08-29 WO PCT/US1991/006195 patent/WO1992004053A1/en not_active Ceased
- 1991-08-30 PT PT98840A patent/PT98840A/en not_active Application Discontinuation
- 1991-08-30 IE IE307191A patent/IE913071A1/en unknown
- 1991-08-30 NZ NZ239617A patent/NZ239617A/en unknown
- 1991-09-01 IL IL99363A patent/IL99363A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0547137A4 (en) | 1993-12-08 |
| CA2090317A1 (en) | 1992-03-01 |
| KR930702029A (en) | 1993-09-08 |
| FI930846A7 (en) | 1993-04-05 |
| EP0547137A1 (en) | 1993-06-23 |
| NZ239617A (en) | 1993-11-25 |
| JPH06500780A (en) | 1994-01-27 |
| WO1992004053A1 (en) | 1992-03-19 |
| FI930846L (en) | 1993-04-05 |
| IL99363A0 (en) | 1992-08-18 |
| AU8506991A (en) | 1992-03-30 |
| IE913071A1 (en) | 1992-03-11 |
| PT98840A (en) | 1992-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI923811A7 (en) | BILDKOMPRESSIONSFOERFARANDE OCH -SYSTEM | |
| FI931745L (en) | TVAOFASIGA AVGIVNINGSFORMULATIONER FOER LIPOFILISKA LAEKEMEDEL | |
| FI930946A0 (en) | KININOGENASINHIBITORER | |
| FI930846A0 (en) | HOMOCONJUGERADE IMMUNOGLOBULINER | |
| FI932054A0 (en) | AGGREGERADE MINERALKOMPOSITPIGMENT | |
| DK0463302T3 (en) | pinchcock | |
| FI932383A0 (en) | Engaongsfoerpackning | |
| FI932324L (en) | Gelbildande floite naeringsfibersammansaettning | |
| FI923758L (en) | EXPRESSIONSSYSTEM | |
| FI924204A7 (en) | FAESTANORDNING FOER UTBYTESKORT | |
| FI932636L (en) | MONTERINGSUNDERLAG FOER GEJDSTAENGER | |
| ITMI911945A0 (en) | LICCIO | |
| DK0558525T3 (en) | Semduramicinpræmiks | |
| FI931906A0 (en) | TUNNSKIKTS EL-ANORDNING | |
| FI932627A7 (en) | Hoegspaenningstransformator Foer en tv-apparat | |
| FI930092L (en) | INDANOPYRROLIDE CARBAMATER | |
| FI931781A0 (en) | PLOEJNINGSVERKTYG | |
| FI925372A0 (en) | FOERBAETTRINGAR ANGAOENDE GEROTORPUMPAR | |
| FI931014A7 (en) | 2-HYDROXI-OCH 2-ACYLOXI-4-MORPHOLINYLANTRACYCLINER | |
| DK164968C (en) | VIRELAAS | |
| FI932081A0 (en) | GEROTORPUMPAR | |
| FI932753L (en) | Identifiersfoerfarande och -system | |
| ATA209290A (en) | DIARAEHMCHEN | |
| FI925407L (en) | MONTERINGSANORDNING FOER BEKLAEDNADSPLATTOR | |
| FI932980L (en) | FASTHAOLLNINGSDON |